Treatment of Patients with Substance Use Disorders Second Edition

Total Page:16

File Type:pdf, Size:1020Kb

Treatment of Patients with Substance Use Disorders Second Edition PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M. Woods, M.D., Ph.D. Joel Yager, M.D. AREA AND COMPONENT LIAISONS Robert Pyles, M.D. (Area I) C. Deborah Cross, M.D. (Area II) Roger Peele, M.D. (Area III) Daniel J. Anzia, M.D. (Area IV) John P. D. Shemo, M.D. (Area V) Lawrence Lurie, M.D. (Area VI) R. Dale Walker, M.D. (Area VII) Mary Ann Barnovitz, M.D. Sheila Hafter Gray, M.D. Sunil Saxena, M.D. Tina Tonnu, M.D. STAFF Robert Kunkle, M.A., Senior Program Manager Amy B. Albert, B.A., Assistant Project Manager Laura J. Fochtmann, M.D., Medical Editor Claudia Hart, Director, Department of Quality Improvement and Psychiatric Services Darrel A. Regier, M.D., M.P.H., Director, Division of Research Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. CONTENTS Statement of Intent. 5 Guide to Using This Practice Guideline . 6 Development Process . 7 Part A: Treatment Recommendations for Patients With Substance Use Disorders . .9 I. Executive Summary of Recommendations . 9 A. Coding System . 9 B. General Treatment Principles . 9 C. Nicotine Use Disorders: Treatment Principles and Alternatives. 12 D. Alcohol Use Disorders: Treatment Principles and Alternatives . 13 E. Marijuana Use Disorders: Treatment Principles and Alternatives . 13 F. Cocaine Use Disorders: Treatment Principles and Alternatives . 13 G. Opioid Use Disorders: Treatment Principles and Alternatives . 14 II. General Treatment Principles . 15 A. Goals of Treatment . 16 B. Assessment . 18 C. Treatment Settings . 22 D. Psychiatric Management. 28 E. Somatic Treatments . 33 F. Psychosocial Treatments . 36 G. Clinical Features Influencing Treatment . 45 H. Legal and Confidentiality Issues . 70 III. Treatment of Nicotine Dependence . 71 A. Overview . 71 B. Assessment . 72 C. Treatment Settings . 74 D. General Approach to Treatment. 74 E. Somatic Treatments . 80 F. Psychosocial Treatments . 82 G. Treatment of Smokers on Smoke-Free Wards. 83 H. Clinical Features Influencing Treatment . 85 IV. Treatment of Alcohol-Related Disorders . 89 A. Overview . 89 B. Treatment Settings . 90 C. Somatic Treatments . 91 Treatment of Patients With Substance Use Disorders 3 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. D. Psychosocial Treatments . 97 E. Clinical Features Influencing Treatment . 100 V. Treatment of Marijuana-Related Disorders . 103 A. Overview . 103 B. Treatment Setting . 103 C. Somatic Treatments. 104 D. Psychosocial Treatments . 104 E. Pregnancy . 104 VI. Treatment of Cocaine-Related Disorders . 105 A. Overview . 105 B. Treatment Settings . 105 C. Somatic Treatments. 106 D. Psychosocial Treatments . 108 E. Clinical Features Influencing Treatment . 109 VII. Treatment of Opioid-Related Disorders. 111 A. Overview . 111 B. Treatment Settings . 112 C. Somatic Treatments. 113 D. Psychosocial Treatments . 120 E. Clinical Features Influencing Treatment . 121 Part B: Background Information and Review of Available Evidence . 124 VIII. Disease Definition, Natural History and Course, and Epidemiology . 124 A. Disease Definition and Diagnostic Features. 124 B. Natural History and Course . 126 C. Epidemiology . 128 IX. Review and Synthesis of Available Evidence . 133 A. Nicotine Dependence. 133 B. Alcohol-Related Disorders . ..
Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Anti-Inflammatory Effects of Amantadine and Memantine
    Journal of Personalized Medicine Communication Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? Félix Javier Jiménez-Jiménez 1,* , Hortensia Alonso-Navarro 1 , Elena García-Martín 2 and José A. G. Agúndez 2 1 Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, E-28500 Madrid, Spain; [email protected] 2 University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, E-10071 Cáceres, Spain; [email protected] (E.G.-M.); [email protected] (J.A.G.A.) * Correspondence: [email protected]; Tel.: +34-636968395 Received: 2 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Abstract: We have reviewed current data on the anti-inflammatory effects of amantadine and memantine in clinical and in vivo models of inflammation, and we propose that these effects have potential interest for the treatment of the SARS-CoV-2 infection (COVID-19 disease). To that end, we performed a literature search using the PubMed Database from 1966 up to October 31 2020, crossing the terms “amantadine” and “memantine” with “inflammation” and “anti-inflammatory”. Amantadine and/or memantine have shown anti-inflammatory effects in chronic hepatitis C, in neuroinflammation induced by sepsis and by lipopolysaccharides, experimental models of multiple sclerosis, spinal cord injury, and respiratory diseases. Since the inflammatory response is one of the main pathogenetic mechanisms in the progression of the SARS-CoV-2 infection, anti-inflammatory effects of amantadine and memantine could be hypothetically useful in the treatment of this condition. This potential utility deserves further research. Keywords: amantadine; memantine; anti-inflammatory effects; SARS-Cov-2; COVID-19; therapy 1.
    [Show full text]
  • Substance Abuse and Dependence
    9 Substance Abuse and Dependence CHAPTER CHAPTER OUTLINE CLASSIFICATION OF SUBSTANCE-RELATED THEORETICAL PERSPECTIVES 310–316 Residential Approaches DISORDERS 291–296 Biological Perspectives Psychodynamic Approaches Substance Abuse and Dependence Learning Perspectives Behavioral Approaches Addiction and Other Forms of Compulsive Cognitive Perspectives Relapse-Prevention Training Behavior Psychodynamic Perspectives SUMMING UP 325–326 Racial and Ethnic Differences in Substance Sociocultural Perspectives Use Disorders TREATMENT OF SUBSTANCE ABUSE Pathways to Drug Dependence AND DEPENDENCE 316–325 DRUGS OF ABUSE 296–310 Biological Approaches Depressants Culturally Sensitive Treatment Stimulants of Alcoholism Hallucinogens Nonprofessional Support Groups TRUTH or FICTION T❑ F❑ Heroin accounts for more deaths “Nothing and Nobody Comes Before than any other drug. (p. 291) T❑ F❑ You cannot be psychologically My Coke” dependent on a drug without also being She had just caught me with cocaine again after I had managed to convince her that physically dependent on it. (p. 295) I hadn’t used in over a month. Of course I had been tooting (snorting) almost every T❑ F❑ More teenagers and young adults die day, but I had managed to cover my tracks a little better than usual. So she said to from alcohol-related motor vehicle accidents me that I was going to have to make a choice—either cocaine or her. Before she than from any other cause. (p. 297) finished the sentence, I knew what was coming, so I told her to think carefully about what she was going to say. It was clear to me that there wasn’t a choice. I love my T❑ F❑ It is safe to let someone who has wife, but I’m not going to choose anything over cocaine.
    [Show full text]
  • Atomoxetine: a New Pharmacotherapeutic Approach in the Management of Attention Deficit/Hyperactivity Disorder
    i26 Arch Dis Child: first published as 10.1136/adc.2004.059386 on 21 January 2005. Downloaded from Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder J Barton ............................................................................................................................... Arch Dis Child 2005;90(Suppl I):i26–i29. doi: 10.1136/adc.2004.059386 Atomoxetine is a novel, non-stimulant, highly selective lifespan including a potential requirement for lifelong treatment.4 Because of the limitations of noradrenaline reuptake inhibitor that has been studied for existing treatments and the paradigm shift in use in the treatment of attention deficit/hyperactivity thinking about the management of ADHD, there disorder (ADHD). Data from clinical trials show it to be well is an interest in the development of new pharmacological treatments. tolerated and effective in the treatment of ADHD in children, adolescents, and adults. Improvements were seen ATOMOXETINE HYDROCHLORIDE: A not only in core symptoms of ADHD, but also in broader NOVEL TREATMENT FOR ADHD social and family functioning and self esteem. Once-daily Atomoxetine is the first non-stimulant to be approved for the treatment of ADHD and the first dosing of atomoxetine has been shown to be effective in drug to be licensed for the treatment of ADHD in providing continuous symptom relief. Atomoxetine does adults.5 Atomoxetine was licensed in the US in not appear to have abuse potential and is associated with November 2002 and in the UK in May 2004. At the time of writing, it is under consideration for a benign side effect profile. The development of licensing by the regulatory authorities in a atomoxetine thus represents an important advance in the number of other countries.
    [Show full text]
  • The Motivational Hallo
    THEMATIC REVIEW Theotivational motivationalhallo helloMANNERS MATTER PART 3 THE With its empathic style, motivational interviewing seems the ideal way to engage new clients in treatment, a psychological handshake which avoids gripping too tightly yet subtly steers the patient in the intended direction. And often it is, as long as we avoid deploying a mechanical arm. by Mike Ashton of THE MANNERS MATTER SERIES is about how services has been on reinforcing motivation, an amalgam of Thanks to Bill Miller, Jim can encourage clients to stay and do well by the acknowledging a problem, wanting help, and resolv- McCambridge, Dwayne Simpson, 5 Don Dansereau, Gerard Connors, manner in which they offer treatment. Parts one and ing that treatment is the help you need. and John Witton for their comments. two dealt with practical issues like reminders, trans- Once thought of as something the patient either Thanks also to Bill Miller, Janice port and childcare. Even at this level, more is in- did or did not have, motivation is now seen as a fluid Brown, Terri Moyers, Paul Amrhein, John Baer and Damaris Rohsenow volved: respect; treating people as individuals; state of mind susceptible to influence. Of the ways for help with obtaining and conveying concern and caring. to exert this influence, motivational interviewing is interpreting their work. Though they 6 have enriched it, none bear any From here on, relationship issues take centre by far the best known. It qualifies for this review responsibility for the final text. stage. Relegated by medicine
    [Show full text]
  • Medication Assisted Treatment MAT
    Medication Assisted Treatment MAT The Root Center provides medication assisted treatment (MAT) for substance use disorders to those who qualify. MAT uses medications in combination with counseling and behavioral therapies to provide a “whole-patient” approach. The ultimate goal of MAT is full recovery, including the ability to live a self-directed life. This treatment approach has been shown to: improve patient survival, increase retention in treatment, decrease illicit opiate and other drug use as well as reduce other criminal activity among people with substance use disorders, increase patients’ ability to gain and maintain employment, and improve birth outcomes among women who have substance use disorders and are pregnant. These approved medications assist with urges, cravings, withdrawal symptoms, and some act as a blocking mechanism for the euphoric effects of alcohol and opioids. Currently, Root offers methadone for opioid use disorder and is considering adding other medications listed below. Opioid Use Disorder Overdose Prevention Methadone Methadone is an opioid treatment medication that reduces withdrawal Naloxone symptoms in people addicted to heroin or other narcotic drugs without Naloxone is a medication which causing the “high” associated with the drug. saves lives by reversing the effects of an opioid overdose. Root Center Methadone is used as a pain reliever and as part of drug addiction patients, their friends and family detoxification and maintenance programs. It is available only from members, can receive a prescription a certified pharmacy. for Naloxone as early as the initial evaluation and throughout treatment. Buprenorphine The medication is administered Buprenorphine is an opioid treatment medication and the combination at the time of the overdose.
    [Show full text]
  • Cocaine Use Disorder
    COCAINE USE DISORDER ABSTRACT Cocaine addiction is a serious public health problem. Millions of Americans regularly use cocaine, and some develop a substance use disorder. Cocaine is generally not ingested, but toxicity and death from gastrointestinal absorption has been known to occur. Medications that have been used as substitution therapy for the treatment of a cocaine use disorder include amphetamine, bupropion, methylphenidate, and modafinil. While pharmacological interventions can be effective, a recent review of pharmacological therapy for cocaine use indicates that psycho-social efforts are more consistent over medication as a treatment option. Introduction Cocaine is an illicit, addictive drug that is widely used. Cocaine addiction is a serious public health problem that burdens the healthcare system and that can be destructive to individual lives. It is impossible to know with certainty the extent of use but data from public health surveys, morbidity and mortality reports, and healthcare facilities show that there are millions of Americans who regularly take cocaine. Cocaine intoxication is a common cause for emergency room visits, and it is one drug that is most often involved in fatal overdoses. Some cocaine users take the drug occasionally and sporadically but as with every illicit drug there is a percentage of people who develop a substance use disorder. Treatment of a cocaine use disorder involves psycho-social interventions, pharmacotherapy, or a combination of the two. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com Pharmacology of Cocaine Cocaine is an alkaloid derived from the Erthroxylum coca plant, a plant that is indigenous to South America and several other parts of the world, and is cultivated elsewhere.
    [Show full text]
  • STRATTERA Safely and Effectively
    1 HIGHLIGHTS OF PRESCRIBING INFORMATION serious cardiac problems that may place them at increased These highlights do not include all the information needed to use vulnerability to its noradrenergic effects. Consideration should be STRATTERA safely and effectively. See full prescribing given to not using STRATTERA in adults with clinically significant information for STRATTERA. cardiac abnormalities. (5.3) ® • Emergent Cardiovascular Symptoms – Patients should undergo STRATTERA (atomoxetine) capsules, for oral use prompt cardiac evaluation. (5.3) Initial U.S. Approval: 2002 • Effects on Blood Pressure and Heart Rate – Increase in blood WARNING: SUICIDAL IDEATION IN CHILDREN AND pressure and heart rate; orthostasis and syncope may occur. Use ADOLESCENTS with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. (5.4) See full prescribing information for complete boxed warning. • Emergent Psychotic or Manic Symptoms – Consider discontinuing • Increased risk of suicidal ideation in children or adolescents treatment if such new symptoms occur. (5.5) (5.1) • Bipolar Disorder – Screen patients to avoid possible induction of a • No suicides occurred in clinical trials (5.1) mixed/manic episode. (5.6) • Aggressive behavior or hostility should be monitored. (5.7) • Patients started on therapy should be monitored closely (5.1) • Possible allergic reactions, including anaphylactic reactions, angioneurotic edema, urticaria, and rash. (5.8) ------------------------INDICATIONS AND USAGE------------------------------- • Effects on Urine Outflow – Urinary hesitancy and retention may STRATTERA® is a selective norepinephrine reuptake inhibitor occur. (5.9) indicated for the treatment of Attention-Deficit/Hyperactivity Disorder • Priapism – Prompt medical attention is required in the event of (ADHD). (1.1) suspected priapism. (5.10, 17) • Growth – Height and weight should be monitored in pediatric -----------------------DOSAGE AND ADMINISTRATION----------------------- patients.
    [Show full text]
  • Downloads/Drugs/…/Guidances/UCM078932
    UCLA UCLA Previously Published Works Title Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Permalink https://escholarship.org/uc/item/7kq6p5tv Journal Scientific reports, 8(1) ISSN 2045-2322 Authors Tian, Jide Dang, Hoa Wallner, Martin et al. Publication Date 2018-11-08 DOI 10.1038/s41598-018-32733-3 Peer reviewed eScholarship.org Powered by the California Digital Library University of California www.nature.com/scientificreports OPEN Homotaurine, a safe blood-brain barrier permeable GABAA-R-specifc agonist, ameliorates disease in Received: 12 April 2018 Accepted: 11 September 2018 mouse models of multiple sclerosis Published: xx xx xxxx Jide Tian, Hoa Dang, Martin Wallner, Richard Olsen & Daniel L. Kaufman There is a need for treatments that can safely promote regulatory lymphocyte responses. T cells express GABA receptors (GABAA-Rs) and GABA administration can inhibit Th1-mediated processes such as type 1 diabetes and rheumatoid arthritis in mouse models. Whether GABAA-R agonists can also inhibit Th17-driven processes such as experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), is an open question. GABA does not pass through the blood-brain barrier (BBB) making it ill-suited to inhibit the spreading of autoreactivity within the CNS. Homotaurine is a BBB-permeable amino acid that antagonizes amyloid fbril formation and was found to be safe but inefective in long-term Alzheimer’s disease clinical trials. Homotaurine also acts as GABAA-R agonist with better pharmacokinetics than that of GABA. Working with both monophasic and relapsing-remitting mouse models of EAE, we show that oral administration of homotaurine can (1) enhance CD8+CD122+PD-1+ and CD4+Foxp3+ Treg, but not Breg, responses, (2) inhibit autoreactive Th17 and Th1 responses, and (3) efectively ameliorate ongoing disease.
    [Show full text]
  • Alcohol Related Dementia and Wernicke-Korsakoff Syndrome
    About Dementia - 18 ALCOHOL RELATED DEMENTIA AND WERNICKE-KORSAKOFF SYNDROME This Help Sheet discusses alcohol related dementia and Wernicke-Korsakoff syndrome, their causes, symptoms and treatment. What is alcohol related dementia? Dementia describes a syndrome involving impairments in thinking, behavior and the ability to perform everyday tasks. Excessive consumption of alcohol over many years can sometimes result in brain damage that produces symptoms of dementia. Alcohol related dementia may be diagnosed when alcohol abuse is determined to be the most likely cause of the dementia symptoms. The condition can affect memory, learning, reasoning and other mental functions, as well as personality, mood and social skills. Problems usually develop gradually. If the person continues to drink alcohol at high levels, the symptoms of dementia are likely to get progressively worse. If the person abstains from alcohol completely then deterioration can be halted, and there is often some recovery over time. Excessive alcohol consumption can damage the brain in many different ways, directly and indirectly. Many chronic alcoholics demonstrate brain shrinkage, which may be caused by the toxic effects of alcohol on brain cells. Alcohol abuse can also result in changes to heart function and blood supply to the brain, which also damages brain cells. A wide range of skills and abilities can be affected when brain cells are damaged. Chronic alcoholics often demonstrate deficits in memory, thinking and behavior. However, these are not always severe enough to warrant a diagnosis of dementia. Many doctors prefer the terms ‘alcohol related brain injury’ or ‘alcohol related brain impairment’, rather than alcohol related dementia, because alcohol abuse can cause impairments in many different brain functions.
    [Show full text]